Investment Analysts’ Recent Ratings Changes for Shattuck Labs (STTK)

A number of research firms have changed their ratings and price targets for Shattuck Labs (NASDAQ: STTK):

• 8/24/2026 – Shattuck Labs is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $18.00 price target on the stock.
• 8/24/2026 – Shattuck Labs is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $18.00 price target on the stock.
• 8/24/2026 – Shattuck Labs was upgraded by TD Cowen to “strong-buy”.
• 8/15/2026 – Shattuck Labs was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/11/2026 – Shattuck Labs had its price target lowered by HC Wainwright from $18.00 to $14.00. They now have a “buy” rating on the stock.
• 7/24/2026 – Shattuck Labs is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $10.00 price target on the stock.
• 7/20/2026 – Shattuck Labs is now covered by Leerink Partners. They set an “outperform” rating and a $16.00 price target on the stock.

Insider Activity

In related news, insider Arundathy N. Pandite sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total transaction of $210,300.00. Following the sale, the insider directly owned 136,219 shares of the company’s stock, valued at $954,895.19. This represents a 18.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Abhinav A. Shukla sold 23,365 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the sale, the insider owned 86,380 shares in the company, valued at approximately $611,570.40. This trade represents a 21.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 53,875 shares of company stock valued at $379,305. 8.79% of the stock is currently owned by company insiders.

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.